Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification

Spinal Cord volume 31, pages 660–666 (1993)Cite this article

Abstract

The goal of the present study was to use intravenous etidronate in the acute phase of heterotopic ossification (HO) in an attempt to achieve a high initial drug concentration at the site of the active ectopic ossification. The study included 27 consecutive patients with an acute onset of HO after spinal cord injury (SCI). The three-phase bone scan was used to confirm clinical diagnosis of HO. Disodium etidronate (Didronel) 300 mg was administered intravenously daily for 3 to 5 days. In 20 patients there was a rapid (1–2 days) decrease of soft tissue swelling (p < 0.01) with no side effects associated with the intravenous administration. In seven patients there was minimal or no improvement of edema after intravenous etidronate. In these patients deep vein thrombosis was found in the affected limbs.

The effect of high dose etidronate on HO was determined in the group of 13 patients with positive clinical and scintigraphic finding of an acute HO, but negative radiographic studies. After intravenous administration of etidronate for 3 days (300 mg/day) the drug was continued orally with 20 mg/kg/day for 6 months. A placebo was not used in this study. In eight patients there was no radiographic evidence of HO after therapy while two patients had minimal ossifications. In three patients therapy was interrupted and all developed HO in 1–2 months.

Download PDF

References

  1. Liberson M (1953) Soft tissue calcification in cord lesion. JAMA 152: 1010–1014.

    CAS  Article  Google Scholar 

  2. Hsu J D, Sakimura I, Stasuffear E S (1975) Heterotopic ossification around the hip joint in spinal cord injury patients. Clin Orthop 112: 165–169.

    Article  Google Scholar 

  3. Wharton G W (1975) Heterotopic ossification. Clin Orthop 112: 142–149.

    Article  Google Scholar 

  4. Stover S L, Hahn H R, Miller J M (1976) Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report). Paraplegia 14: 146–156.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Finerman G A M, Stover S L (1981) Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis 1981 3: 337–342.

    CAS  Article  Google Scholar 

  6. Khari M R A, Johnston C C (1977) Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). Clin Orthop 127: 94–104.

    Google Scholar 

  7. Recker R R, Saville P D (1973) Intestinal absorption of disodium ethane-1-hydroxy-l-disphosphonate (EHDP) using a deconvolution technique. Toxicol Appl Pharmacol 24: 580–589.

    CAS  Article  Google Scholar 

  8. Garland D E, Alday B, Venos K G, Vogt J C (1983) Disphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clin Orthop 176: 197–200.

    Google Scholar 

  9. Garland D E (1990) A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop 263: 13–28.

    Google Scholar 

  10. Barnhart E R (1992) Physicians' Desk Reference. 46th ed. Med Econom Comp Inc, Montvale, NJ.

  11. Kanis J A, Urwin G H, Gray R E S, Beneton M N C, McCloskey E V, Hamdy N A T et al (1987) Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 82(2A): 55–70.

    CAS  Article  Google Scholar 

  12. Garattini S, Guaitani A, Mantovani A (1987) Effect of etidronate disodium on the interactions between malignancy and bone. Am J Med 82(2A): 29–33.

    CAS  Article  Google Scholar 

  13. Hasling C, Charles P, Mosekilde L (1987) Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 82(2A): 51–54.

    CAS  Article  Google Scholar 

  14. Jacobs T P, Gordon A C, Silverberg S J, Shane E, Reich L, Clemens T L et al (1987) Neoplastic hypercalcemia: Physiologic response to intravenous etidronate disodium. Am J Med 82(2A): 42–50.

    CAS  Article  Google Scholar 

  15. Meunier P J, Chapuy M C, Delmas P, Charhon S, Edouard C, Arlot M (1987) Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy: Effects on biochemical parameters and bone histomorphometry. Am J Med 82(2A): 75–78.

    Google Scholar 

  16. Singer F R, Fernandez M (1987) Therapy of hypercalcemia of malignancy. Am J Med 82(2A): 34–41.

    CAS  Article  Google Scholar 

  17. Thiebaud D, Jaeger P, Gobelet C, Jacquet A F, Burckhard P A (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 85: 207–212.

    CAS  Article  Google Scholar 

  18. Freed J H, Hashn H, Menter R, Dillon T (1982) The use of the three-phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of didronel therapy. Paraplegia 20: 208–216.

    CAS  Google Scholar 

  19. Fleisch H (1987) Bisphosphonates. In: Christiansen C, editor. Osteoporosis. International Symposium on Osteoporosis: 7–12.

    Google Scholar 

  20. Fleisch H (1984) Diphosphonates and osteoporosis. In: Barzel UB, editor. Osteoporosis. 11th ed. Grune & Stration, NY: 205–222.

    Google Scholar 

  21. Fleisch H, Russell R G G, Francis M D (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262–1264.

    CAS  Article  Google Scholar 

  22. Francis M D, Russell R G G, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264–1266.

    CAS  Article  Google Scholar 

  23. Nakahara N, Yoshikawa H, Tokjaoka I, Ono K (1990) Effects of ethane-1-hydroxy-1, 1-diphosphosphonate on ectopic bone formation induced by murine osteosarcoma-derived bone-inducing substance. Bone 7: 229–233.

    Article  Google Scholar 

  24. Flora L, Hassing G S, Cloyd G G, Bevan J A, Parfitt A M, Villanueva A R (1981) The long-term skeletal effects of EHDP in dogs. Metab Bone Dis 4/5: 289–300.

    Article  Google Scholar 

  25. Johnston C C, Altma R D, Canfield R E, Fienman G A M, Taubee J D, Ebert M L (1983) Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). Clin Orthop 172: 186–194.

    Google Scholar 

  26. Sadar E S, Walton R J, Gossman H H (1972). Neurological dysfunction in Paget's disease of the vertebral column. J Neurosurg 37: 661–665.

    CAS  Article  Google Scholar 

  27. Douglas D L, Kanis J A, Duckworth T, Beard D J, Paterson A D, Russell R G G (1981) Paget's disease: Improvement of spinal cord dysfunction with disphosphonates and calcitonin. Metab Bone Dis 4/5: 327–336.

    Article  Google Scholar 

  28. Francis M D, Flora L, King W R (1972) The effects of disodium ethane- 1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tiss Res 9: 109–121.

    CAS  Article  Google Scholar 

  29. Flora L (1979) Comparative anti-inflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22: 340–346.

    CAS  Article  Google Scholar 

  30. Cecchini M C, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Min Res 5: 1019–1027.

    CAS  Article  Google Scholar 

  31. Aida Y, Toda Y, Shimakoski Y, Yamada K, Anono M . Effect of disodium ethane- 1-hydroxy-1, 1-disphosphonate (DHDP) on interleukin 1 production by macrophages. Microbiol Immunol 30: 1199–1206.

  32. Rossier A B, Bussat Ph, Infante F, Zanbder R, Courvoisier B, Muheaim G et al (1973) Current facts on para-osteo-arthropathy (POA). Paraplegia 11: 36–78.

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Orthopaedics and Rehabilitation, University of Miami School of Medicine, PO Box 016960, Miami, 33101, Florida, USA

    K Banovac, F Gonzalez & J J Bowker

  2. Jackson Memorial Medical Centre, Miami, Florida, USA

    Nancy Wade

Authors
  1. K Banovac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J J Bowker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Banovac, K., Gonzalez, F., Wade, N. et al. Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Spinal Cord 31, 660–666 (1993). https://doi.org/10.1038/sc.1993.106

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sc.1993.106

Keywords

  • heterotopic ossification
  • paraplegia
  • spinal cord injury
  • bisphosphonate

Further reading

Search

Advanced search

Quick links